AI Article Synopsis
- * In a randomized controlled trial, 24 patients received either a placebo or levosimendan before surgery, with measurements taken at various intervals to evaluate heart performance.
- * Results showed that those receiving levosimendan had significant improvements in cardiac index and left ventricular ejection fraction, suggesting it could be an effective treatment during this type of surgery.
Article Abstract
Aim: To determine if levosimendan could improve cardiac performance during off-pump coronary artery bypass grafting in patients with normal preoperative left ventricular function.
Methods: Twenty-four patients included in this double-blind randomized controlled trial received either placebo (n=12) or 12 microg/kg loading dose of levosimendan (n=12) during a period of 15 minutes before the surgery. The heart rate, cardiac index, stroke volume index, and left ventricular ejection fraction were measured before and 10 and 60 minutes after the drug administration.
Results: The baseline measurements of hemodynamic parameters did not differ between the groups. Heart rate was not significantly different between the placebo and levosimendan group. Compared with placebo group, cardiac index and left ventricular ejection fraction were significantly higher 10 and 60 minutes (p=0.018 for all) after administration of levosimendan. After 60 minutes, the cardiac index increased from the baseline value of 2.18 to 2.84 L/min/m2. Left ventricular ejection fraction increased by 14% after 10 minutes, and by 10% after 60 minutes. Stroke volume index was significantly higher at 10 minutes (p=0.018), but not at 60 minutes (p=0.063) after the administration of levosimendan.
Conclusion: Administration of 12 microg/kg of levosimendan enhances the left ventricular performance and offers a promising therapeutic option during off-pump coronary artery bypass grafting in patients with good preoperative left ventricular function.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Experience with sodium glucose cotransporter-2 inhibitors in adult patients with Fontan circulation.
Adv Clin Exp Med
January 2025
Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland.
Background: We still know little about the effective pharmacological treatment of heart failure (HF) associated with the Fontan circulation. One of the new options may be sodium glucose cotransporter-2 inhibitors (SGLT2i), which have been proven effective in classic forms of left ventricular HF.
Objectives: To evaluate the effect and safety of SGLT2i inclusion in adults with Fontan circulation.
Evaluating cardiac performance in beagle dogs: Transesophageal echocardiography and myocardial work assessment.
Heliyon
January 2025
Department of Ultrasound Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, People's Republic of China.
Objectives: This study aimed to establish standard transesophageal echocardiographic (TEE) measurements of left ventricular (LV) morphology, function, and myocardial work parameters in healthy Beagle dogs using pressure-strain loops (PSL). Additionally, it sought to standardize optimal TEE imaging techniques and explore the potiential application of myocardial work analyis in veterinary medicine.
Methods: Thirty-seven healthy male Beagle dogs were anesthetized, intubated, and mechanically ventilated for TEE examinations.
Paroxysmal Complete Atrioventricular Block With Complete Left Bundle Branch Block Treated With Left Bundle Branch Area Pacing: A Case Report.
Cureus
December 2024
Clinical Engineering, Soseikai General Hospital, Kyoto, JPN.
Left bundle branch area pacing (LBBAP) can effectively enhance cardiac contraction by engaging the conduction system. LBBAP, compared with right ventricular apex pacing, can reduce QRS duration and enhance left ventricular function. Consequently, LBBAP has been proposed as a viable alternative to cardiac resynchronization therapy (CRT).
View Article and Find Full Text PDFImpact of Preventive Intravenous Amiodarone on Reperfusion Ventricular Fibrillation in Patients With Left Ventricular Hypertrophy Undergoing Open-Heart Surgery: Randomized Controlled Clinical Trial.
JMIR Form Res
January 2025
Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China, 86 2568303569.
Background: Ventricular fibrillation (VF) is a vicious arrhythmia usually generated after removal of the aortic cross-clamp (ACC) in patients undergoing open-heart surgery, which could damage cardiomyocytes, especially in patients with left ventricular hypertrophy (LVH). Amiodarone has the prominent properties of converting VF and restoring sinus rhythm. However, few studies concentrated on the effect of amiodarone before ACC release on reducing VF in patients with LVH.
View Article and Find Full Text PDF[Hypertrophic cardiomyopathy with left ventricular excessive trabeculation resulting from MYBPC3 gene mutation: a case report].
Zhonghua Xin Xue Guan Bing Za Zhi
January 2025
Department of Magnetic Resonance Imaging, Fuwai Hospital, National Center for Cardiovascular Diseases of China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing100037, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!